Cargando…
Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut)
BACKGROUND: Orphan medicines show some characteristics that hinder the evaluation of their clinical added value. The often low level of evidence available for orphan drugs, together with a high budget impact and an incremental cost-effectiveness ratio many times higher than drugs used for non-orphan...
Autores principales: | Guarga, Laura, Badia, Xavier, Obach, Mercè, Fontanet, Manel, Prat, Alba, Vallano, Atonio, Torrent, Josep, Pontes, Caridad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598260/ https://www.ncbi.nlm.nih.gov/pubmed/31248421 http://dx.doi.org/10.1186/s13023-019-1121-6 |
Ejemplares similares
-
Early Access to Medicines: Use of Multicriteria Decision Analysis (MCDA) as a Decision Tool in Catalonia (Spain)
por: Gasol, Montse, et al.
Publicado: (2022) -
Description of the use of multicriteria to support pricing and reimbursement decisions by European health technology assessment bodies
por: Elvira, David, et al.
Publicado: (2021) -
A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)
por: de Andrés-Nogales, Fernando, et al.
Publicado: (2021) -
Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs
por: Schey, C., et al.
Publicado: (2017) -
Development and pilot of a multicriteria decision analysis (MCDA) tool for health services administrators
por: Blythe, Robin, et al.
Publicado: (2019)